Press "Enter" to skip to content

Arthritis Drug Reduces Covid 19 Related Deaths

According to the World Health organisation, Combining two inflammation-blocking drugs reduces hospitalization and death from Covid-19 compared with standard therapy.The study was published in the Journal of the American Medical Association.The Health Agency also said that adding drugs that block an immune protein called interleukin-6 to an already widely used treatment, corticosteroids, reduces the risk of death and the need for breathing assistance. The recommendation was based on 27 trials involving almost 11,000 people.

Interleukin-6 can be generated when severely ill Covid-19 patients’ immune systems overreact. This prompted health organisation researchers to examine the benefit of treating people hospitalized with the disease with drugs that block its effects. They found that the drugs were effective when used with corticosteroids, reducing the risk of death by 17% compared with corticosteroids alone. The risk of dying was also 21% lower for patients not on ventilation.

Claire Vale, principal research fellow at the MRC Clinical Trials Unit at University College London said that these results, which will lead to better outcomes for patients hospitalized with Covid-19, reflect a huge global effort. Results showed the risk of dying within 28 days was lower in patients receiving drugs that blocked interleukin-6 along with corticosteroids.

In this group, the risk of death was 21% compared with 25% in those receiving standard care. This means that for every 100 such patients, four more will survive.The study was coordinated by the WHO together with King’s College London, University of Bristol, University College London and Guy’s and St Thomas’ NHS Foundation Trust.Janet Diaz, head of clinical management at WHO Health Emergencies said that to an extent of global vaccine inequality, people in the lowest income countries will be the ones most at risk of severe and critical Covid-19. Those are the people these drugs need to reach.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *